Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
36,958,246

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.37 +0.07 (0.25%) 5:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Should Value Investors Pick Pfizer (PFE) Stock Right Now?

Is Pfizer (PFE) a great pick from the value investor's perspective right now? Read on to know more.

Sweta Killa headshot

Small-Cap ETF (DWAS) Hits New 52-Week High

This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?

Devyani Chamria headshot

3 mREIT Stocks to Buy Amid Vaccine Hopes & Thanksgiving Cheer

The overall optimism in the market, thanks to the positive news on the vaccine front and strong rebound in the economy creates a favorable backdrop for mortgage REITs like AGNC, NLY, and RC.

Vaccine News Propels Market Higher: 5 Potential Gainers

Promising vaccine news aided the market in moving higher with further economic recovery in sight, making it a good time to invest in fundamentally sound names like EnPro (NPO) and APi Group (APG).

Tirthankar Chakraborty headshot

Thanksgiving Brings Strong Seasonal Market Trends: 5 Picks

Traditionally, the stock market tends to perform well from the Thanksgiving week till the end of the year. This calls for investing in growth stocks like General Motors (GM) & Malibu Boats (MBUU).

Nilanjan Banerjee headshot

Permian Producers in Focus as Crude Price Picks Up

Improving oil prices are definitely a boon for Permian explorers like Devon (DVN), Diamondback (FANG), Concho (CXO) and Matador (MTDR).

Sanghamitra Saha headshot

Dow Hits 30K for First Time: 7 Stocks Driving the ETF Rally

Wall Street seemed super-excited as the Dow Jones reached 30,000 for the first time in history on Nov 24.

Sanghamitra Saha headshot

ETFs to Play as Vaccine News Looks to Outdo Virus Fear

After almost a year-long wait, the month of November started delivering sweet surprises to investors in the form of back-to-back vaccine news.

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

Sweta Killa headshot

Spread of Top-Ranked Value ETFs to Bet on Vaccine Optimism

The potential arrival of a coronavirus vaccine will end the pandemic crisis, keeping the economy recovery intact, and will boost consumer spending and in turn lift value stocks.

Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.

Kinjel Shah headshot

How Does AstraZeneca's COVID-19 Vaccine Data Compare to Others'?

Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.

Sweta Killa headshot

5 ETFs That Gained in Double Digits Last Week

Inside the ETFs that gained in double-digits last week.

Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III

Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.

3 Coronavirus Vaccine Makers Near Finish Line in November

Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.

Sweta Killa headshot

Celebrate Thanksgiving Week With These ETFs

Thanksgiving week is here and history shows that this holiday-shortened week is a bullish feast for stock investors.

Sanghamitra Saha headshot

5 Top-Performing Leveraged ETF Areas of Last Week

Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.

Matador Resources (MTDR) Up 50.4% MTD: What's Driving It?

Improving oil prices on encouraging coronavirus vaccine news aid Matador Resources (MTDR).

Tirthankar Chakraborty headshot

Cyclical Stocks Pop on Vaccine Progress: 5 Solid Buys

Positive news on the COVID-19 vaccine front revitalized the U.S. economy and vis-a-vis cyclical stocks like General Motors (GM), Delta Apparel (DLA) and Deere (DE).

Sanghamitra Saha headshot

5 Top-Performing ETFs of Last Week

Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.

Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment

The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.

Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Sanghamitra Saha headshot

4 Sectors to Prosper in Thanksgiving Week

Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.

Mark Vickery headshot

Markets Up on Sunny Holiday Outlook

The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.

Mark Vickery headshot

AstraZeneca-Oxford Vaccine at 70% Efficacy

One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.